Silence Therapeutics plc
Zerlasiran
High Lp(a)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Zerlasiran in High Lp(a) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Extra-hepatic Preclinical data Results from first industry CVOT in high Lp(a) anticipated in 2026”